TNF registered in Europe: does TNF get a second chance?
Eggermont
A M
AM
Department of Surgical Oncology, University Hospital Rotterdam-Den Hoed Cancer Center, Rotterdam, The Netherlands.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D010478:Chemotherapy, Cancer, Regional Perfusion; D003131:Combined Modality Therapy; D017277:Drug Approval; D005060:Europe; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy*; D008558:Melphalan / Q000627:therapeutic use; D012509:Sarcoma / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000627:therapeutic use*
D000276:Adjuvants, Immunologic; D018906:Antineoplastic Agents, Alkylating; D014409:Tumor Necrosis Factor-alpha; D008558:Melphalan